A common mechanism of resistance is the isolation of a new subpopulation with a mutation resistant to the original drug, such as identified in BCR-ABL in leukemias[224-226] and ALK in neuroblastoma[227,228] (the development of these mutations are described below). This evidence concerns the gene ABL1 and leukemia.